vs
南玻集团（CSGS）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
南玻集团的季度营收约是Orthofix Medical Inc.的1.5倍（$323.1M vs $219.9M），南玻集团净利率更高（2.2% vs -1.0%，领先3.2%），南玻集团同比增速更快（2.0% vs 2.0%），南玻集团自由现金流更多（$55.8M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 4.6%）
中国南玻集团股份有限公司是中国规模最大的建筑玻璃生产商，业务涵盖浮法玻璃、建筑玻璃、显示玻璃、汽车玻璃、镀膜玻璃、镜子、彩滤玻璃、太阳能玻璃及节能玻璃等各类玻璃产品的研发、生产与销售，产品广泛应用于建筑、消费电子、新能源汽车、光伏等多个领域。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
CSGS vs OFIX — 直观对比
营收规模更大
CSGS
是对方的1.5倍
$219.9M
营收增速更快
CSGS
高出0.1%
2.0%
净利率更高
CSGS
高出3.2%
-1.0%
自由现金流更多
CSGS
多$39.0M
$16.8M
两年增速更快
OFIX
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $323.1M | $219.9M |
| 净利润 | $7.0M | $-2.2M |
| 毛利率 | 50.0% | 71.1% |
| 营业利润率 | 9.0% | 0.2% |
| 净利率 | 2.2% | -1.0% |
| 营收同比 | 2.0% | 2.0% |
| 净利润同比 | -79.7% | 92.4% |
| 每股收益（稀释后） | $0.24 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSGSOFIX
| Q4 25 | $323.1M | $219.9M | ||
| Q3 25 | $303.6M | $205.6M | ||
| Q2 25 | $297.1M | $203.1M | ||
| Q1 25 | $299.5M | $193.6M | ||
| Q4 24 | $316.7M | $215.7M | ||
| Q3 24 | $295.1M | $196.6M | ||
| Q2 24 | $290.3M | $198.6M | ||
| Q1 24 | $295.1M | $188.6M |
净利润CSGSOFIX
| Q4 25 | $7.0M | $-2.2M | ||
| Q3 25 | $20.5M | $-22.8M | ||
| Q2 25 | $12.3M | $-14.1M | ||
| Q1 25 | $16.1M | $-53.1M | ||
| Q4 24 | $34.5M | $-29.1M | ||
| Q3 24 | $19.1M | $-27.4M | ||
| Q2 24 | $13.8M | $-33.4M | ||
| Q1 24 | $19.5M | $-36.0M |
毛利率CSGSOFIX
| Q4 25 | 50.0% | 71.1% | ||
| Q3 25 | 48.1% | 72.2% | ||
| Q2 25 | 49.5% | 68.7% | ||
| Q1 25 | 48.4% | 62.8% | ||
| Q4 24 | 51.3% | 69.0% | ||
| Q3 24 | 49.4% | 68.7% | ||
| Q2 24 | 47.3% | 67.8% | ||
| Q1 24 | 46.5% | 67.5% |
营业利润率CSGSOFIX
| Q4 25 | 9.0% | 0.2% | ||
| Q3 25 | 10.0% | -8.3% | ||
| Q2 25 | 10.0% | -7.9% | ||
| Q1 25 | 9.8% | -25.2% | ||
| Q4 24 | 13.4% | -5.3% | ||
| Q3 24 | 10.8% | -9.6% | ||
| Q2 24 | 8.8% | -12.5% | ||
| Q1 24 | 10.8% | -15.6% |
净利率CSGSOFIX
| Q4 25 | 2.2% | -1.0% | ||
| Q3 25 | 6.7% | -11.1% | ||
| Q2 25 | 4.1% | -6.9% | ||
| Q1 25 | 5.4% | -27.4% | ||
| Q4 24 | 10.9% | -13.5% | ||
| Q3 24 | 6.5% | -13.9% | ||
| Q2 24 | 4.8% | -16.8% | ||
| Q1 24 | 6.6% | -19.1% |
每股收益（稀释后）CSGSOFIX
| Q4 25 | $0.24 | $-0.05 | ||
| Q3 25 | $0.73 | $-0.57 | ||
| Q2 25 | $0.44 | $-0.36 | ||
| Q1 25 | $0.57 | $-1.35 | ||
| Q4 24 | $1.20 | $-0.76 | ||
| Q3 24 | $0.67 | $-0.71 | ||
| Q2 24 | $0.48 | $-0.88 | ||
| Q1 24 | $0.68 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.0M | $82.0M |
| 总债务越低越好 | $539.5M | — |
| 股东权益账面价值 | $283.7M | $450.0M |
| 总资产 | $1.5B | $850.6M |
| 负债/权益比越低杠杆越低 | 1.90× | — |
8季度趋势，按日历期对齐
现金及短期投资CSGSOFIX
| Q4 25 | $180.0M | $82.0M | ||
| Q3 25 | $158.4M | $62.9M | ||
| Q2 25 | $145.9M | $65.6M | ||
| Q1 25 | $136.0M | $58.0M | ||
| Q4 24 | $161.8M | $83.2M | ||
| Q3 24 | $118.4M | $30.1M | ||
| Q2 24 | $110.4M | $26.4M | ||
| Q1 24 | $120.8M | $27.0M |
总债务CSGSOFIX
| Q4 25 | $539.5M | — | ||
| Q3 25 | $538.6M | $157.2M | ||
| Q2 25 | $537.8M | $157.0M | ||
| Q1 25 | $537.6M | $156.9M | ||
| Q4 24 | $538.5M | $157.0M | ||
| Q3 24 | $539.5M | $118.5M | ||
| Q2 24 | $540.5M | $118.0M | ||
| Q1 24 | $541.5M | $118.2M |
股东权益CSGSOFIX
| Q4 25 | $283.7M | $450.0M | ||
| Q3 25 | $289.5M | $442.5M | ||
| Q2 25 | $290.7M | $458.3M | ||
| Q1 25 | $283.1M | $458.3M | ||
| Q4 24 | $282.6M | $503.1M | ||
| Q3 24 | $288.4M | $525.9M | ||
| Q2 24 | $273.3M | $546.0M | ||
| Q1 24 | $269.3M | $570.3M |
总资产CSGSOFIX
| Q4 25 | $1.5B | $850.6M | ||
| Q3 25 | $1.5B | $832.6M | ||
| Q2 25 | $1.4B | $837.2M | ||
| Q1 25 | $1.4B | $823.1M | ||
| Q4 24 | $1.5B | $893.3M | ||
| Q3 24 | $1.4B | $867.9M | ||
| Q2 24 | $1.4B | $882.0M | ||
| Q1 24 | $1.3B | $906.0M |
负债/权益比CSGSOFIX
| Q4 25 | 1.90× | — | ||
| Q3 25 | 1.86× | 0.36× | ||
| Q2 25 | 1.85× | 0.34× | ||
| Q1 25 | 1.90× | 0.34× | ||
| Q4 24 | 1.91× | 0.31× | ||
| Q3 24 | 1.87× | 0.23× | ||
| Q2 24 | 1.98× | 0.22× | ||
| Q1 24 | 2.01× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $59.2M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $55.8M | $16.8M |
| 自由现金流率自由现金流/营收 | 17.3% | 7.6% |
| 资本支出强度资本支出/营收 | 1.1% | 4.9% |
| 现金转化率经营现金流/净利润 | 8.46× | — |
| 过去12个月自由现金流最近4个季度 | $141.4M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流CSGSOFIX
| Q4 25 | $59.2M | $27.7M | ||
| Q3 25 | $47.9M | $12.4M | ||
| Q2 25 | $37.3M | $11.6M | ||
| Q1 25 | $11.5M | $-18.4M | ||
| Q4 24 | $82.5M | $23.7M | ||
| Q3 24 | $39.5M | $11.7M | ||
| Q2 24 | $43.1M | $9.0M | ||
| Q1 24 | $-29.4M | $-18.6M |
自由现金流CSGSOFIX
| Q4 25 | $55.8M | $16.8M | ||
| Q3 25 | $43.9M | $2.5M | ||
| Q2 25 | $34.6M | $4.5M | ||
| Q1 25 | $7.1M | $-25.1M | ||
| Q4 24 | $76.6M | $15.2M | ||
| Q3 24 | $32.0M | $6.3M | ||
| Q2 24 | $38.8M | $-360.0K | ||
| Q1 24 | $-34.1M | $-29.1M |
自由现金流率CSGSOFIX
| Q4 25 | 17.3% | 7.6% | ||
| Q3 25 | 14.5% | 1.2% | ||
| Q2 25 | 11.6% | 2.2% | ||
| Q1 25 | 2.4% | -13.0% | ||
| Q4 24 | 24.2% | 7.0% | ||
| Q3 24 | 10.8% | 3.2% | ||
| Q2 24 | 13.4% | -0.2% | ||
| Q1 24 | -11.6% | -15.4% |
资本支出强度CSGSOFIX
| Q4 25 | 1.1% | 4.9% | ||
| Q3 25 | 1.3% | 4.8% | ||
| Q2 25 | 0.9% | 3.5% | ||
| Q1 25 | 1.5% | 3.5% | ||
| Q4 24 | 1.9% | 4.0% | ||
| Q3 24 | 2.5% | 2.7% | ||
| Q2 24 | 1.5% | 4.7% | ||
| Q1 24 | 1.6% | 5.6% |
现金转化率CSGSOFIX
| Q4 25 | 8.46× | — | ||
| Q3 25 | 2.34× | — | ||
| Q2 25 | 3.04× | — | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | 2.39× | — | ||
| Q3 24 | 2.07× | — | ||
| Q2 24 | 3.12× | — | ||
| Q1 24 | -1.51× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
